接触石棉与肝内胆管癌风险增加：潜在因果关联的更多证据。
Exposure to Asbestos and Increased Intrahepatic Cholangiocarcinoma Risk: Growing Evidences of a Putative Causal Link.
机构信息
Division of Oncology, IRCCS, Azienda Ospedaliero-Universitaria of Bologna, IT.
Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, IT.
出版信息
Ann Glob Health. 2022 Jun 13;88(1):41. doi: 10.5334/aogh.3660. eCollection 2022.
Abstract
To date the true global incidence of intrahepatic cholangiocarcinoma (iCCA) and the underlying risk factors remain to be fully defined, in particular, the role of occupational and environmental factors. Currently, the putative role of asbestos exposure as a risk factor for iCCA is gaining increased attention in the international scientific community and agencies. In this commentary we review and integrate available epidemiological and mechanistic evidences that support a potential role of asbestos exposure in iCCA etiology.
摘要
迄今为止，肝内胆管癌（iCCA）的真实全球发病率及其潜在危险因素仍未得到充分确定，特别是职业和环境因素的作用。目前，国际科学界和机构越来越关注石棉暴露作为 iCCA 危险因素的潜在作用。在这篇评论中，我们回顾并整合了现有的流行病学和机制证据，这些证据支持石棉暴露在 iCCA 病因学中的潜在作用。
相似文献
1
Exposure to Asbestos and Increased Intrahepatic Cholangiocarcinoma Risk: Growing Evidences of a Putative Causal Link.
Ann Glob Health. 2022 Jun 13;88(1):41. doi: 10.5334/aogh.3660. eCollection 2022.
2
Asbestos exposure as an additional risk factor for small duct intrahepatic cholangiocarcinoma: a pilot study.
Sci Rep. 2023 Feb 13;13(1):2580. doi: 10.1038/s41598-023-27791-1.
3
Asbestos and Intrahepatic Cholangiocarcinoma.
Cells. 2020 Feb 12;9(2):421. doi: 10.3390/cells9020421.
4
Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis.
J Hepatol. 2020 Jan;72(1):95-103. doi: 10.1016/j.jhep.2019.09.007. Epub 2019 Sep 16.
5
Asbestos: a hidden player behind the cholangiocarcinoma increase? Findings from a case-control analysis.
Cancer Causes Control. 2013 May;24(5):911-8. doi: 10.1007/s10552-013-0167-3. Epub 2013 Feb 14.
6
Cholangiocarcinoma miscoding in hepatobiliary centres.
Eur J Surg Oncol. 2021 Mar;47(3 Pt B):635-639. doi: 10.1016/j.ejso.2020.09.039. Epub 2020 Oct 1.
7
Hilar cholangiocarcinoma: pathology and tumor biology.
Front Med China. 2010 Dec;4(4):371-7. doi: 10.1007/s11684-010-0130-6. Epub 2010 Nov 25.
8
Highlights of topic "Etiology and epidemiology of cholangiocarcinoma".
J Hepatobiliary Pancreat Sci. 2014 May;21(5):299-300. doi: 10.1002/jhbp.90.
9
Update on the association of hepatitis B with intrahepatic cholangiocarcinoma: Is there new evidence?
World J Gastroenterol. 2021 Jul 21;27(27):4252-4275. doi: 10.3748/wjg.v27.i27.4252.
10
Bile duct adenoma may be a precursor lesion of small duct type intrahepatic cholangiocarcinoma.
Histopathology. 2021 Jan;78(2):310-320. doi: 10.1111/his.14222. Epub 2020 Sep 15.
引用本文的文献
1
Integrated transcriptomic analysis identifies lactylation-linked gemcitabine resistance and therapeutic targets in intrahepatic cholangiocarcinoma.
Front Cell Dev Biol. 2025 Sep 1;13:1611434. doi: 10.3389/fcell.2025.1611434. eCollection 2025.
2
Mapping the landscape of biliary tract cancer in Europe: challenges and controversies.
Lancet Reg Health Eur. 2025 Feb 19;50:101171. doi: 10.1016/j.lanepe.2024.101171. eCollection 2025 Mar.
3
Cholangiocarcinoma and Occupational Exposure to Asbestos: Insights From the Italian Pooled Cohort Study.
Med Lav. 2024 Apr 24;115(2):e2024016. doi: 10.23749/mdl.v115i2.14649.
4
Quantitative Assessment of Asbestos Fibers in Abdominal Organs: A Scoping Review.
Med Lav. 2023 Dec 7;114(6):e2023048. doi: 10.23749/mdl.v114i6.14946.
5
The exposome and liver disease - how environmental factors affect liver health.
J Hepatol. 2023 Aug;79(2):492-505. doi: 10.1016/j.jhep.2023.02.034. Epub 2023 Mar 6.
本文引用的文献
1
Intrahepatic cholangiocarcinoma development in a patient with a novel BAP1 germline mutation and low exposure to asbestos.
Cancer Genet. 2020 Oct;248-249:57-62. doi: 10.1016/j.cancergen.2020.10.001. Epub 2020 Oct 11.
2
Cholangiocarcinoma 2020: the next horizon in mechanisms and management.
Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):557-588. doi: 10.1038/s41575-020-0310-z. Epub 2020 Jun 30.
3
Cumulative asbestos exposure and mortality from asbestos related diseases in a pooled analysis of 21 asbestos cement cohorts in Italy.
Environ Health. 2019 Aug 7;18(1):71. doi: 10.1186/s12940-019-0510-6.
4
Trends in surgery and disparities in receipt of surgery for intrahepatic cholangiocarcinoma in the US: 2005-2014.
J Gastrointest Oncol. 2019 Apr;10(2):339-347. doi: 10.21037/jgo.2018.12.07.
5
Asbestos fiber identification in liver from cholangiocarcinoma patients living in an asbestos polluted area: a preliminary study.
Tumori. 2019 Oct;105(5):404-410. doi: 10.1177/0300891619839305. Epub 2019 Mar 27.
6
Cholangiocarcinoma: Epidemiology and risk factors.
Liver Int. 2019 May;39 Suppl 1:19-31. doi: 10.1111/liv.14095. Epub 2019 Mar 24.
7
Integrative Molecular Characterization of Malignant Pleural Mesothelioma.
Cancer Discov. 2018 Dec;8(12):1548-1565. doi: 10.1158/2159-8290.CD-18-0804. Epub 2018 Oct 15.
8
Detecting germline BAP1 mutations in patients with peritoneal mesothelioma: benefits to patient and family members.
J Transl Med. 2018 Jul 13;16(1):194. doi: 10.1186/s12967-018-1559-7.
9
Overview of BAP1 cancer predisposition syndrome and the relationship to uveal melanoma.
J Curr Ophthalmol. 2018 Mar 22;30(2):102-109. doi: 10.1016/j.joco.2018.02.005. eCollection 2018 Jun.
10
Nuclear BAP1 loss is common in intrahepatic cholangiocarcinoma and a subtype of hepatocellular carcinoma but rare in pancreatic ductal adenocarcinoma.
Cancer Genet. 2018 Aug;224-225:21-28. doi: 10.1016/j.cancergen.2018.03.002. Epub 2018 Apr 9.
Zotero 插件